Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 14/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905841 | 0.92 | PPARA (0.57) | CHRM4PPARANPC1ALDH1A1GAA | |
| SCHEMBL3892372 | 0.90 | PPARA (0.65) | CHRM4PPARAGAAPPARGPPARD | |
| SCHEMBL5487834 | 0.85 | PPARA (0.60) | CHRM4PPARANPC1ALDH1A1GAA | |
| SCHEMBL3896903 | 0.83 | NPC1 (0.44) | CHRM4PPARANPC1ALDH1A1GAA | |
| SCHEMBL3890236 | 0.83 | PPARA (0.63) | CHRM4PPARAGAAPPARGPPARD | |
| SCHEMBL3888967 | 0.83 | PPARA (0.68) | CHRM4PPARANPC1GAAPPARG | |
| SCHEMBL3892378 | 0.83 | PPARA (0.68) | CHRM4PPARANPC1GAAPPARG | |
| SCHEMBL3888972 | 0.83 | PPARA (0.68) | CHRM4PPARANPC1GAAPPARG | |
| SCHEMBL5489160 | 0.79 | FFAR1 (0.39) | CHRM4PPARANPC1ALDH1A1GAA | |
| SCHEMBL3889698 | 0.78 | PPARA (0.64) | CHRM4PPARAGAAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1862464-A1 | NOVEL CYCLIC AMINOPHENYLALKANOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | CHRM4 2809/4885PPARA 1/4885NPC1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.